Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -92.40% is 71% above its 2-year average of -317.36%, near the high end of its 2-year range (-768.79%–-8.33%).
18.09% below its 12-month average of -78.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -16.91%.
EBITDA MARGIN
-92.40%
EBITDA MARGIN AVG TTM
-78.24%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-18.09%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Xilio Therapeutics, Inc.
Market Cap
$59.18M
EBITDA Margin
-92.40%
TTM Avg
-78.24%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.44M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.43M
EBITDA Margin
-270.28%
TTM Avg
-442.93%
3Y Avg
-1031.00%
5Y Avg
-861.19%
Market Cap
$60.02M
EBITDA Margin
-753.96%
TTM Avg
-753.96%
3Y Avg
-753.96%
5Y Avg
-753.96%
Market Cap
$58.29M
EBITDA Margin
-3226.05%
TTM Avg
-3226.05%
3Y Avg
-3226.05%
5Y Avg
-3226.05%
Market Cap
$58.06M
EBITDA Margin
-16170.91%
TTM Avg
-8243.87%
3Y Avg
-8243.87%
5Y Avg
-8243.87%
Market Cap
$60.42M
EBITDA Margin
-99843.01%
TTM Avg
-70984.01%
3Y Avg
-70984.01%
5Y Avg
-70984.01%
Market Cap
$57.61M
EBITDA Margin
-48157.14%
TTM Avg
-48157.14%
3Y Avg
-25368.35%
5Y Avg
-13932.36%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $59.18M | -92.40% | -78.24% | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | -270.28% | -442.93% | -1031.00% | -861.19% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | -753.96% | -753.96% | -753.96% | -753.96% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | -3226.05% | -3226.05% | -3226.05% | -3226.05% |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | -16170.91% | -8243.87% | -8243.87% | -8243.87% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | -48157.14% | -48157.14% | -25368.35% | -13932.36% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
Gross Margin
99.5%
EBITDA Margin
-92.4%
Operating Margin
-95.9%
Net Margin
-34.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -16.91% |
| 2026-03-31 | -108.86% |
| 2025-12-31 | -84.12% |
| 2025-09-30 | -8.33% |
| 2025-06-30 | -173.00% |
| 2025-03-31 | -455.77% |
| 2024-12-31 | -768.79% |
| 2024-09-30 | -635.48% |
| 2024-06-30 | -604.96% |
